Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI7J1L)

• Drug Name: A-740003 Drug Info
• Synonyms: A-740003; 861393-28-4; A 740003; n-(1-(((cyanoamino)(5-quinolinylimino)methyl)amino)-2,2-dimethylpropyl)-3,4-dimethoxybenzeneacetamide; (E)-N-(1-((cyanamido(quinolin-5-ylamino)methylene)amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide; CHEMBL255787; SCHEMBL3357263; MolPort-044-567-676; EX-A1789; AKOS022184697; RL05324; CS-0297; Benzeneacetamide, N-(1-(((cyanoamino)(5-quinolinylamino)methylene)amino)-2,2-dimethylpropyl)-3,4-dimethoxy-; HY-50697; Benzeneacetamide, N-(1-(((cyanoamino)(5-quinolinylimino)methyl)ami

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 23232014
  CAS Number: CAS 861393-28-4
  TTD Drug ID: DMI7J1L

Molecule-Related Drug Atlas

Drug(s) Targeting P2X purinoceptor 7 (P2RX7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CE-224535	DMFCLT6	Arthralgia	ME82	Phase 2/3	[3]
AZD9056	DMJGYPK	Chronic obstructive pulmonary disease	CA22	Phase 2	[4]
LY3857210	DMZO2V2	Pain	MG30-MG3Z	Phase 2	[5]
BIL010t	DMV1EA9	Alzheimer disease	8A20	Phase 1/2	[6]
EVT 401	DMOG8IE	Rheumatoid arthritis	FA20	Phase 1	[7]
SGM-1019	DMDAHEL	Inflammatory bowel disease	DD72	Phase 1	[8]
GSK1482160	DMWDQOV	Pain	MG30-MG3Z	Phase 1	[9]
JNJ-55308942	DM0QZJX	Anhedonia	MB24.2	Phase 1	[6]
JNJ-54175446	DMQ5ZVK	Major depressive disorder	6A70.3	Phase 1	[10]
JNJ-479655	DMDU6GN	Alzheimer disease	8A20	Clinical trial	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2X purinoceptor 7 (P2RX7)	TT473XN	P2RX7_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4119).
• [2] Purinergic P2X(7) receptor antagonists: Chemistry and fundamentals of biological screening. Bioorg Med Chem. 2009 Jul 15;17(14):4861-5.
• [3] Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
• [4] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [6] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [7] Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40.